Institut Pasteur Korea is an infectious disease-focused research institute that utilizes proprietary platforms to identify novel molecular targets and discover small molecules to diagnose, treat and address unmet global public health needs. It was established as a nonprofit private research institute in Apr. 2004 by a collaboration between the Korean government and Institut Pasteur to strategically combine Institut Pasteur's strength in biomedical research with Korean expertise in information technology. Over the past 130 years, Institut Pasteur’s worldwide reputation for groundbreaking research has been distinguished with ten Nobel Prizes. Institut Pasteur Korea has been a key driver of early drug discovery among the 33 members of the Institut Pasteur International Network located in 29 countries on 5 continents, including China, Cambodia, Laos, Vietnam and Korea within Asia. For over a decade, the institute has provided fundamental technologies and tools to bridge between Korean and international bio-pharma science. Integrating biology, IT and chemistry, Institut Pasteur Korea has focused on technology development to build the best platform for high content screening performed in BSL level 2 and 3 environments; resulting in discovery of a new best-in-class molecule to fight tuberculosis. Researchers at Institut Pasteur Korea also focus on discovery biology to study and understand the disease, and on developing new and more effective ways to diagnose and treat it. Leveraging its unique drug discovery capabilities and global partnerships, Institut Pasteur Korea also tackles antibacterial resistance, HCV/HBV, influenza, leishmaniasis, tuberculosis and cancer. With the excellence of its multinational staff, cutting-edge translational-driven research, strong affiliation with Institut Pasteur and its international network, and commitment to improving people’s lives, Institut Pasteur Korea aims to be one of the premier research institutions in Korea.